Prolyl Hydroxylase inhibitor 1 is an orally active inhibitor of hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) (IC50 of 62.23 nM).

AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages. AKB-6899 leads to stabilization of HIF-2α which induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth.

Chloramphenicol (Chloromycetin), a broad-spectrum antibiotic, blocks bacterial protein synthesis.

Adaptaquin is an inhibitor of the hypoxia-inducing factor prolyl hydroxylase (HIF-PH) [1] [2].

PHD-1-IN-1 is a potent inhibitor of hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme(IC50 = 0.034 μM).

PHD2-IN-1, a potent and orally active HIF prolyl hydroxylase 2 (PHD2) inhibitor, exhibits an IC50 of 22.53 nM and is applicable in anemia research [1].

Diethyl pyimDC is an inhibitor of human collagen prolyl 4-hydroxylase 1 (CP4H1).

E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.

Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase that stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 (HIF-2). Potential for HIF-1α-related diseases (including peripheral vascular disease (PVD), heart failure, coronary artery disease (CAD), ischaemia, anaemia, colitis and other inflammatory bowel diseases).

HIF-PHD-IN-1 is a pharmacological compound that acts as an orally active inhibitor of the hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), displaying an IC50 of 54 nM for hHIF-PHD2. Its potential as a therapeutic agent for renal anemia is highly promising.

Chloramphenicol stearate is an antibiotic useful for the therapy of numbers of bacterial infections. This includes an eye ointment to treat conjunctivitis.

Dextramycine is an optic isomer of chloramphenicol.